In the present study, to delve into the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) combined with temozolomide (TMZ) on high-grade glioma cells and related mechanism, six cases of high-grade glioma cells from patient’s tumor tissues were cultured. 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide (MTT) assay was performed to detect cell proliferation and toxicity. Flow cytometry was performed to...
Tue Jun 23, 2020 03:00
Somatostatine analogs (SSAs) are currently indicated in the treatment of acromegaly and neuroendocrine tumors (NETs). Actually, pregnancy in patients with acromegaly and NETs does not represent an exceptional event because reproductive behavior has changed in the last decades and patients with NETs show more frequently long-term survival. The safety profile of SSAs during pregnancy is still controversial. Concerning acromegaly, based on case reports and series, SSAs administration during pregnancy...
Tue Jun 23, 2020 03:00
Background A high percentage of small cell lung cancer (SCLC) cases harbor cell cycle–related gene mutations and RICTOR amplification. Based on underlying somatic mutations, the authors have conducted a phase 2 biomarker‐driven, multiarm umbrella study. Methods The SCLC Umbrella Korea StudiES (SUKSES) is an adaptive platform trial that undergoes continual modification according to the observed outcomes. This study included 286 patients with SCLC who failed platinum therapy and who had known...
Thu Jun 25, 2020 17:11
British Journal of Cancer, Published online: 29 June 2020; doi:10.1038/s41416-020-0965-9Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor
03:00
British Journal of Cancer, Published online: 29 June 2020; doi:10.1038/s41416-020-0955-yAn effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia
03:00
British Journal of Cancer, Published online: 29 June 2020; doi:10.1038/s41416-020-0961-0Seropositivity for Helicobacter pylori and hepatobiliary cancers in the PLCO study
03:00
British Journal of Cancer, Published online: 29 June 2020; doi:10.1038/s41416-020-0962-zA comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
03:00
British Journal of Cancer, Published online: 29 June 2020; doi:10.1038/s41416-020-0957-9Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature
03:00
British Journal of Cancer, Published online: 29 June 2020; doi:10.1038/s41416-020-0953-0New tools to prevent cancer growth and spread: a ‘Clever’ approach
03:00
01:18
01:18
01:18
01:18
British Journal of Cancer, Published online: 26 June 2020; doi:10.1038/s41416-020-0960-1COVID-19 and cancer research
Fri Jun 26, 2020 03:00
British Journal of Cancer, Published online: 26 June 2020; doi:10.1038/s41416-020-0926-3How promising is phototherapy for cancer?
Fri Jun 26, 2020 03:00
British Journal of Cancer, Published online: 26 June 2020; doi:10.1038/s41416-020-0949-9Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
Fri Jun 26, 2020 03:00
Fri Jun 26, 2020 01:12
LncRNA TUG1 Promotes Hepatocellular Carcinoma Migration and Invasion Via Targeting miR-137/AKT2 Axis
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Wed Jun 24, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Tue Jun 23, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Tue Jun 23, 2020 10:00
Abstract Transgenic green fluorescent protein (GFP) gene mice are widely used. And for the unique advantages of immunodeficient animals in the field of oncology research, we aim to establish a nude mouse inbred strain, which stably expresses EGFP (enhanced‐GFP) for the use of transplanted tumor microenvironment (TME) research. Female C57BL/6‐Tg(CAG‐EGFP) mice were backcrossed with male BALB/c nude mice for eleven generations. The genotype and phenotype of novel inbred strain Foxn1nu.B6‐Tg(CAG‐EGFP)...
Fri Jun 26, 2020 17:45
Abstract Receptor tyrosine kinases (RTKs) and Yes‐associated protein (YAP) are critical driving factors in tumors. Currently, the regulation of RTKs in the Hippo‐YAP pathway has been recognized as an important issue. However, the relationship between AXL, one of the RTKs, and YAP in head and neck squamous cell carcinoma (HNSCC) remains unknown. In this study, the crosstalk between AXL and YAP was thoroughly investigated in vitro and in vivo . We determined that there was a positive correlation...
Fri Jun 26, 2020 17:44
Abstract Structural DNA nanotechnology enables DNA to be used as nanomaterials for novel nanostructure construction with unprecedented functionalities. Artificial DNA nanostructures can be designed and generated with precisely controlled features, resulting in its utility in bionanotechnological and biomedical applications. A tetrahedral DNA nanostructure (TDN), the most popular DNA nanostructure, with high stability and simple synthesis procedure, is a promising candidate as nanocarriers in drug...
Fri Jun 26, 2020 17:44
Abstract To analyze the association between exosomal miR‐766‐3p expression levels in the serum and the prognosis of esophageal squamous cell carcinoma (ESCC). The serum global exosomal microRNA expression of ESCC patients was measured by microRNA microarray. Quantitative real‐time polymerase chain reactions (qRT‐PCR) were used to analyze the expression levels of candidate microRNAs in both serum and tissues from ESCC patients. Wilcoxon tests were applied to evaluate clinical characteristics and...
Fri Jun 26, 2020 17:44
Abstract Immunotoxins are antibody‐cytotoxin chimeric molecule with mighty cytotoxicity. Programmed cell death 1 ligand 1 (PD‐L1), is a transmembrane protein expressed mainly in inflammatory tumor tissues and plays a pivotal role in immune escape and tumor progression. Although PD‐L1 immune checkpoint therapy has been successful in some cases, many patients have not benefited enough in the end due to primary/secondary resistance. In order to optimize the therapeutic efficacy of anti‐PD‐L1 monoclonal...
Fri Jun 26, 2020 17:44
Abstract Aberrant activation of ERK (extracellular signal‐regulated kinase) signaling is a hallmark of lung cancer. Although constitutively activating mutations of EGFR (epidermal growth factor receptor) and KRAS contribute to the hyperactivation of ERK1/2, other mechanisms remain elusive. In this study, the zinc finger protein ZNF251 was found to be upregulated in clinical lung cancer samples, and it promoted the growth of lung cancer cells and the growth of primary lung KPC cells from mouse models...
Fri Jun 26, 2020 17:39
Tumor Immune Microenvironment and Immune Checkpoint Inhibitors in Esophageal Squamous Cell Carcinoma
Summary Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological type of esophageal cancer, predominantly constituting 90% of cases worldwide. Despite the development of multidisciplinary therapeutic approaches, its prognosis remains unfavorable. Recently, the development of monoclonal antibodies inhibiting programmed death 1 (PD‐1) or programmed death‐ligand 1 (PD‐L1) has led to remarkable therapeutic responses among multiple malignancies including ESCC. However, only a few...
Wed Jun 24, 2020 19:30
Abstract Alveolar soft part sarcoma (ASPS), epithelioid sarcoma (ES), and clear cell sarcoma (CCS) are known to be chemoresistant tumors. The aim of this study is to investigate the effect of pazopanib on these chemoresistant tumors. This study is designed as a single arm, multicenter, investigator‐initiated phase II trial. Patient enrollment was conducted between July 2016 and August 2018 at 10 hospitals participating in the Japanese Musculoskeletal Oncology Group (JMOG). The primary endpoint is...
Wed Jun 24, 2020 19:29
Abstract The telomere is the specialized nucleoprotein complex at the end of the chromosome. Its highly conserved 5′‐TTAGGG‐3′ repeats and shelterin protein complexes form a protective loop structure to maintain the integrity and stability of linear chromosomes. Although human somatic cells gradually shorten telomeres to undergo senescence or crisis, cancer cells activate telomerase or the recombination‐based mechanism to maintain telomeres and exhibit immortality. As the most frequent non‐coding...
Wed Jun 24, 2020 19:21
Abstract Remdesivir (RDV), a single diastereomeric monophosphoroamidate prodrug that inhibits viral RNA polymerases, has potent in vitro antiviral activity against SARS‐CoV2. RDV received FDA’s emergency use authorization in United States and approval in Japan for treatment of severe COVID‐19 patients. This report describes two phase 1 studies that evaluated the safety and pharmacokinetics (PK) of single escalating and multiple intravenous (IV) doses of RDV (solution or lyophilized formulation)...
Fri Jun 26, 2020 19:39
Abstract Umibecestat, an orally active β‐secretase (BACE‐1) inhibitor, reduces the production of amyloid beta (Aβ)‐peptide that accumulates in the brain of patients with Alzheimer's disease. The ECG effects of umibecestat, on QTcF (Fridericia‐corrected QT), on PR and QRS and heart rate (HR), were estimated by concentration‐effect modeling. Three phase‐I/II studies with durations up to 3 months, with 372 healthy subjects over a wide age range, including both sexes and two ethnicities, were pooled,...
Thu Jun 25, 2020 13:23
Abstract Non‐alcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma. There are currently no FDA approved treatments for NAFLD; however, this is a field of active research. This review summarizes emerging pharmacotherapies for the treatment of adult and pediatric NAFLD. Investigated pharmacotherapies predominantly target bile acid signaling, insulin resistance and lipid handling within...
Thu Jun 25, 2020 13:21
Abstract Healthcare expenditure on pharmaceuticals, especially innovative oncology drugs, is escalating. Current knowledge on this topic is largely limited to studies conducted upon reimbursement of new drugs. We investigated how endogenous factors (eg, changed reimbursement criteria, such as an expanded indication) and exogenous factors (eg, competing drugs) affect the level and trends of innovative oncology drug utilization in the Taiwan National Health Insurance (NHI) system, both upon reimbursement...
Thu Jun 25, 2020 13:19
Abstract This study aimed to predict long‐term progression‐free survival (PFS) using early M‐protein dynamic measurements in patients with relapsed/refractory multiple myeloma (MM). The PFS was modeled based on dynamic M‐Protein data from two phase 3 studies, POLLUX and CASTOR, which included 569 and 498 patients with relapsed/refractory multiple myeloma, respectively. Both studies compared active controls (lenalidomide and dexamethasone, and bortezomib and dexamethasone, respectively) alone vs....
Thu Jun 25, 2020 13:19
Purpose: Natural Killer (NK) cells play a critical role in tumor immunosurveillance. Multiple activating and inhibitory receptors regulate NK cell-mediated tumor control. The inhibitory receptor TIGIT and its counter-receptor CD226 exert opposite effects on NK cell-mediated tumor reactivity. Experimental design: We evaluated the frequency, phenotype and functions of NK cells freshly isolated from healthy donors and melanoma patients with multiparameter flow cytometry. We assessed TIGIT and CD226...
Fri Jun 26, 2020 16:17
Purpose: This phase 2 study tested granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells (GVAX) and ipilimumab in metastatic pancreatic ductal adenocarcinoma (PDA) in the maintenance setting. Methods: Patients with PDA who were treated with front-line chemotherapy consisting of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in the metastatic setting and had ongoing response or stable disease after 8-12 doses were eligible. Patients...
Fri Jun 26, 2020 16:17
PURPOSE: Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent pre-clinical activity against ROS1 G2032R solvent-front mutation among others. We report the first-in-human US-phase 1 results of taletrectinib. PATIENTS AND METHODS: Patients ≥18 years old with neuroendocrine tumors, with tumor-induced pain, or tumors harboring ROS1/NTRK rearrangements were eligible. Accelerated titration followed by modified continuous reassessment method and escalation...
Fri Jun 26, 2020 16:17
Purpose: Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumor promoting role for HIF-2α, and a tumor suppressor role for HIF-1α. However, few studies have comprehensively examined the clinical relevance of this paradigm. Furthermore, the hypoxia associated factor (HAF), which regulates the HIFs,...
Thu Jun 25, 2020 16:44
Purpose: Tumor mutational burden (TMB) has emerged as a potential predictive biomarker for clinical response to ICI therapy, but whether TMB also predicts toxicity remains unknown. We investigated the relationship between TMB, objective response rate (ORR), overall survival (OS), and toxicity for ICI therapy across multiple cancer types. Methods: We searched MEDLINE, PubMed, and ASCO/ESMO/AACR meetings for clinical trials of anti-PD(L)1, CTLA-4, or combination in 29 cancer types. We assessed ICI...
Thu Jun 25, 2020 16:44
Purpose: We evaluated the prognostic and predictive value of circulating tumor cells (CTCs) hormone-receptor positive (HR+) metastatic breast cancer (MBC) patients randomized to letrozole (Let) alone or letrozole plus bevacizumab (Let+Bev) in the first-line setting (CALGB 40503). Experimental Design: Blood samples were collected at pretreatment and three additional time points during therapy. The presence of ≥5 CTCs per 7.5 mLs of blood was considered CTC-positive. Association of CTCs with progression-free...
Thu Jun 25, 2020 16:44
Purpose: The study goal was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody (mAb) targeting effector regulatory T cells (eTregs), in combination with mAb checkpoint inhibitors durvalumab or tremelimumab. Experimental Design: This was a multicenter, phase I, dose-escalation study, followed by disease specific cohort expansion (NCT02301130). Mogamulizumab dose escalation proceeded with concurrent dose escalation of durvalumab or...
Thu Jun 25, 2020 16:44
Publication date: Available online 26 June 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Cristian Lolli, Amelia Altavilla, Vincenza Conteduca, Alberto Farolfi, Chiara Casadei, Giuseppe Schepisi, Giuseppe Luigi Banna, Ugo De Giorgi
Sat Jun 27, 2020 18:38
Publication date: Available online 26 June 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): David J. Stewart, Dominick Bosse, Andrew Robinson, Michael Ong, Michael Fung-Kee-Fung, Stephanie Brule, John F. Hilton, Alberto Ocana
Sat Jun 27, 2020 18:38
Opinion statement Patients with stage IV or recurrent/metastatic non-small cell lung cancer (NSCLC) whose tumors harbor high PD-L1 expression and driver mutations with approved targeted treatments (EGFR, ALK, BRAFV600E, ROS1) should receive initial therapy with targeted therapy based on impressive clinical activity. PD-(L)1 inhibitors have demonstrated minimal activity in many driver mutation subsets including EGFR and ALK and appears to have more benefit in smoking-associated...
Thu Jun 25, 2020 03:00
Publication date: Available online 27 June 2020Source: European Journal of CancerAuthor(s): Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, Sylvestre Le Moulec, Umberto Basso, Alison Birtle, Alastair Thomson, Michael Krainer, Aline Guillot, Ugo De Giorgi, Ali Hasbini, Gedske Daugaard, Amit Bahl, Simon Chowdhury, Orazio Caffo, Philippe Beuzeboc, Dominique Spaeth, Jean-Christophe Eymard, Aude Fléchon, Jerome Alexandre
Sun Jun 28, 2020 17:03
Publication date: Available online 25 June 2020Source: European Journal of CancerAuthor(s): Roch Houot, Ronald Levy, Guillaume Cartron, Philippe Armand
Fri Jun 26, 2020 23:15
Publication date: Available online 27 June 2020Source: European Journal of Surgical OncologyAuthor(s): Ashok R. Shaha, Ronald Ghossein, R. Michael Tuttle
Sun Jun 28, 2020 18:46
Publication date: Available online 27 June 2020Source: European Journal of Surgical OncologyAuthor(s): Xiang Wang, Jing Sun, Weiteng Zhang, Xinxin Yang, Ce Zhu, Bujian Pan, Yunpeng Zeng, Jingxuan Xu, Xiaodong Chen, Xian Shen
Sat Jun 27, 2020 16:49
Publication date: Available online 26 June 2020Source: European Journal of Surgical OncologyAuthor(s): Ashok R. Shaha, Vincent Vander Poorten, R. Michael Tuttle
Sat Jun 27, 2020 16:49
Publication date: Available online 24 June 2020Source: European Journal of Surgical OncologyAuthor(s): Leonie T. Jonker, Sharon Hendriks, Maarten MH. Lahr, Barbara C. van Munster, Geertruida H. de Bock, Barbara L. van Leeuwen
Thu Jun 25, 2020 22:15
Annually, increasing numbers of OXA-244-producing Escherichia coli in 13 German federal states prompted us to initiate an outbreak investigation. Whole genome sequencing revealed that among 148 isolates analysed, most belonged to sequence type 38 with 62 isolates forming a genetically distinct cluster. Although no epidemiological link could be identified between cases, ongoing investigations suggest non-healthcare associated transmission. A screening-PCR was developed facilitating early detection...
Thu Jun 25, 2020 03:00
Introduction Invasive meningococcal disease (IMD) is a rare condition with a high case fatality rate. While most patients suffer from one single episode in life, there is anecdotal evidence for recurrent infection. Aim The German National Reference Laboratory for Meningococci and Haemophilus influenzae (NRZMHi) analysed IMD cases from 2002 to 2018 to retrospectively quantify the risk of recurrent infection. Methods Recurrent IMD was defined as detection of Neisseria meningitidis...
Thu Jun 25, 2020 03:00
We investigated why a clinical meticillin-resistant Staphylococcus aureus (MRSA) isolate yielded false-negative results with some commercial PCR tests for MRSA detection. We found that an epidemic European CC1-MRSA-IV clone generally exhibits this behaviour. The failure of the assays was attributable to a large insertion in the orfX/SCCmec integration site. To ensure the reliability of molecular MRSA tests, it is vital to monitor emergence of new SCCmec types and junction sites.
Thu Jun 25, 2020 03:00
Sentinel surveillance of acute hospitalisations in response to infectious disease emergencies such as the 2009 influenza A(H1N1)pdm09 pandemic is well described, but recognition of its potential to supplement routine public health surveillance and provide scalability for emergency responses has been limited. We summarise the achievements of two national paediatric hospital surveillance networks relevant to vaccine programmes and emerging infectious diseases in Canada (Canadian Immunization Monitoring...
Thu Jun 25, 2020 03:00
The advent of COVID-19, has posed a risk that human respiratory samples containing human influenza viruses may also contain SARS-CoV-2. This potential risk may lead to SARS-CoV-2 contaminating conventional influenza vaccine production platforms as respiratory samples are used to directly inoculate embryonated hen’s eggs and continuous cell lines that are used to isolate and produce influenza vaccines. We investigated the ability of these substrates to propagate SARS-CoV-2 and found that neither could...
Thu Jun 25, 2020 03:00
Future Oncology, Ahead of Print.
Sat Jun 27, 2020 13:09
Future Oncology, Ahead of Print.
Sat Jun 27, 2020 12:54
Future Oncology, Ahead of Print.
Thu Jun 25, 2020 13:09
Future Oncology, Ahead of Print.
Thu Jun 25, 2020 10:59
Related Articles Cancer management challenge in a developing country in COVID-19 pandemic: reflection of a group of Moroccan oncologists. Future Oncol. 2020 Jun 25;: Authors: Mrabti H, Berrada N, Raiss G, Ettahri H, Abahssain H, Bourhafour M, Sahraoui S, Errihani H Abstract Management of cancer patients during the COVID-19 pandemic is a worldwide challenge - in particular in developing countries where the risk of saturation of health facilities...
Fri Jun 26, 2020 15:03
Related Articles Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Jun 25;: Authors: Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M Abstract Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic...
Fri Jun 26, 2020 15:03
Related Articles Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. Future Oncol. 2020 Jun 24;: Authors: Norz V, Lawaczeck L, Bedke J, Rausch S, Stenzl A Abstract Prostate cancer is a major health issue with an incidence of 1,100,000 worldwide. Eventually, 20-40% of curatively treated patients will face a biochemical recurrence. Lately, the treatment...
Thu Jun 25, 2020 15:28
Abstract PAX5 is a member of the paired box (PAX) family of transcription factors involved in B‐cell development. PAX5 P80R has recently been described as a distinct genetic B‐cell precursor (BCP) ALL subtype with a favorable prognosis in adults. In contrast, an unfavorable outcome has been observed in children. Our aim was to determine the frequency of PAX5 P80R in childhood BCP‐ALL treated according to the AIEOP‐BFM ALL 2000 protocol and to evaluate its clinical significance within this study...
Sat Jun 27, 2020 22:29
Abstract Cancer may complicate the clinical course of non‐valvular atrial fibrillation (AF) but its association with cardiovascular events (CVEs) is still unclear. We performed a prospective cohort study including 2092 consecutive AF patients on vitamin K antagonists. Principal endpoint was the occurrence of CVEs including fatal/non‐fatal myocardial infarction (MI) and ischemic stroke/TIA and cardiovascular death. Secondary endpoints were major adverse cardiac events (MACE) and thromboembolism (TE)....
Thu Jun 25, 2020 20:58
Abstract The performance of cervical cancer screening will decline as a function of lower disease prevalence ‐ a consequence of successful human papillomavirus (HPV) vaccination. Replacement of cytology with molecular HPV testing as the primary screening test and adoption of risk‐based screening, with less intense screening of vaccinated individuals and initiated at older ages is expected to improve efficiency. However, policy officials may decide to further reduce or eliminate screening as the...
Thu Jun 25, 2020 20:57
Abstract Genome‐wide association studies (GWAS) have identified many genetic risk variants for cancers. The utility of these variants in assessing risk of esophageal, gastric, and endometrial cancers, as well as melanoma, glioma, diffuse large B‐cell lymphoma, follicular lymphoma, chronic lymphoid leukemia, and multiple myeloma, has not been adequately investigated. We constructed a site‐specific polygenic risk score (PRS) for each of these nine cancers using their GWAS‐identified risk variants....
Thu Jun 25, 2020 20:56
Abstract First described as a neuronal cell adhesion molecule, L1CAM was later identified to be present at increased levels in primary tumors and metastases of various types of cancer. Here, we describe the multifaceted roles of L1CAM that are involved in diverse fundamental steps during tumor initiation and progression, as well as in chemoresistance. Recently, Ganesh et al. reported that L1CAM identifies metastasis‐initiating cells in colorectal carcinoma exhibiting stem‐like cell features, increased...
Thu Jun 25, 2020 20:56
Abstract Platinum‐based chemotherapy(PBC) has proven benefits in phase III studies for advanced triple‐negative breast cancer(TNBC) patients; however, real‐world data of large samples from multiple centers are lacking. This study was to compare the effectiveness of PBC and non‐PBC in advanced TNBC patients in multicenter real‐world settings. Totally, 495 patients with advanced TNBC receiving PBC(n = 350) or non‐PBC(n = 145) at four cancer centers in China between 2003 and 2019 were included. Treatment...
Thu Jun 25, 2020 20:55
Abstract Previous studies have observed a reduced mortality risk associated with menopausal hormone therapy (MHT) use among breast cancer survivors. We sought to clarify whether such association could be explained by tumor heterogeneity, specific causes of death, confounding from co‐morbidities or health behaviors, and a comparison group of women without breast cancer. We interviewed 1508 women newly diagnosed with first primary breast cancer in 1996‐1997 (~3 months after diagnosis), and 1556 age‐matched...
Thu Jun 25, 2020 20:55
Abstract The HLA locus on chromosome 6 has been reported to be associated with cervical cancer. We investigated two independent single‐nucleotide polymorphisms in a large case‐control series of cervical dysplasia and carcinoma that has been newly established by the German Cervigen Consortium, comprising a total of 2481 cases and 1556 healthy females. We find significant associations for both variants, rs9272117 at HLA‐DQA1, and rs2844511 at MICA and HCP5 , with cervical disease. Both variants...
Wed Jun 24, 2020 12:06
Abstract Metabolic syndrome (MetS) and its components may link to pancreatic cancer risk, however, current epidemiological evidence is limited, and the potential mechanisms underlying the associations remain unclear. To investigate this, we carried out the prospective cohort study of 474 929 participants without a diagnosis of cancer based on UK Biobank dataset. MetS was defined according to the International Diabetes Federation criteria and pancreatic cancer was identified through linkage to U.K....
Wed Jun 24, 2020 12:05
Abstract First‐line treatment of pediatric low‐grade glioma using surgery, radio‐ or chemotherapy fails in a relevant proportion of patients. We analyzed efficacy of subsequent surgical and non‐surgical therapies of the German cohort of the SIOP‐LGG 2004 study (2004 to 2012, 1558 registered patients; median age at diagnosis 7.6 years, median observation time 9.2 years, overall survival 98%/96% at 5/10 years, 15% neurofibromatosis type 1 [NF1]). During follow‐up, 1078/1558 patients remained observed...
Wed Jun 24, 2020 12:05
Abstract Little is known about the association of diet with risk of bladder cancer. This might be due to the fact that the majority of studies have focused on single food items, rather than dietary patterns, which may better capture any influence of diet on bladder cancer risk. We aimed to investigate the association between a measure of Western dietary pattern and bladder cancer risk. Associations between adherence to a Western dietary pattern and risk of developing bladder cancer were assessed...
Wed Jun 24, 2020 12:04
Abstract Cancer is the leading cause of mortality in Canada. Undergraduate medical education therefore must ensure adequate oncology education for all physicians and inspire some to make oncology their career specialty, in an effort to ensure public care needs are met in the future. Medical student-led oncology interest groups (OIGs) are a subset of specialty interest groups that supplement formal didactic and clinical learning to increase exposure to oncology and access to mentors....
Sat Jun 27, 2020 03:00
Abstract Communication skills training is standardly offered to health professionals working in cancer; however, there is no consensus on the precise style or duration of training, which is most effective. This study aimed to examine the experiences of health professionals who had participated in either a 1-day communication skills training workshop focusing on experiential learning or a 2-h workshop in which participants discussed different communication styles demonstrated on...
Fri Jun 26, 2020 03:00
Abstract The hidden curriculum is the set of implicit influences which occur within health care organizations. The hidden curriculum has a tremendous impact on medical trainees and practicing physicians alike due to its influence in the domains of policy development, evaluation, resource allocation and institutional slang. We explore and reflect on the various ways in which the hidden curriculum impacts medical trainees and professionals in academic medical institutions.
Fri Jun 26, 2020 03:00
Abstract Dignity is a core topic within palliative care, and thus, it is important to get a detailed assessment of healthcare providers’ (HCPs) perspectives on this subject. This study aimed to explore various HCPs’ perspectives on end-of-life patients’ dignity by collecting different testimonies about what dignity entails and which strategies HCPs use to maintain patients’ dignity. A sample of 104 participants was interviewed using two open questions to collect qualitative data....
Thu Jun 25, 2020 03:00
Abstract The creation of antitumor agents with an oral or subcutaneous route of administration has had important positive implications in the development of drugs to treat cancers, but issues such as false drug intake, uncontrolled side effects, and limited supervision may jeopardize the ability of these agents to improve treatment. A potential solution is the recruitment of non-physician healthcare professionals (i.e., nurses and physician assistants) and a special training course...
Thu Jun 25, 2020 03:00
Abstract Chronic hepatitis C virus (HCV) increases the risk for hepatocellular carcinoma. Despite higher prevalence of HCV in persons born 1945–1965 (baby boomer), screening has not been widely adopted. Both primary care providers (PCPs) and associate care providers (ACPs) need to be educated about the rationale and methods to screen for HCV. In five Federally Qualified Health Centers serving low-income Hispanic communities, PCPs and ACPs attended a 50-min training lecture about...
Thu Jun 25, 2020 03:00
Publication date: Available online 28 June 2020Source: Practical Radiation OncologyAuthor(s): Bo Qiu, Shi Pei Lu, Bin Wang, Jian Hui Shao, Ying Ting Zhang, Meng Yun Qiang, Jin Yu Guo, Yin Zhou, Hai Hang Jiang, Cheng Guang Lin, Xiao Yan Huang, Xiao Wu Deng, Qi Wen Li, Hui Liu
Sun Jun 28, 2020 20:20
Publication date: Available online 27 June 2020Source: Practical Radiation OncologyAuthor(s): W. Jeffrey Zabel, Jessica L. Conway, Adam Gladwish, Julia Skliarenko, Giulio Didiodato, Leah Goorts-Matthews, Adam Michalak, Sarah Reistetter, Jenna King, Keith Nakonechny, Kyle Malkoske, Muoi N. Tran, Nevin McVicar
Sat Jun 27, 2020 14:05
Publication date: July–August 2020Source: Practical Radiation Oncology, Volume 10, Issue 4Author(s):
Thu Jun 25, 2020 18:48
Publication date: July–August 2020Source: Practical Radiation Oncology, Volume 10, Issue 4Author(s):
Thu Jun 25, 2020 18:48
Publication date: July–August 2020Source: Practical Radiation Oncology, Volume 10, Issue 4Author(s):
Thu Jun 25, 2020 18:48
Dear Editor
Sat Jun 27, 2020 03:00
We would like to thank Iqbal et al. for their interest in our article [1].
Fri Jun 26, 2020 03:00
Target volume delineation has always been but has become increasingly challenging in radiation oncology given the ever more prevalent use of techniques such as 3D conformal radiation therapy and intensity-modulated radiation therapy (IMRT) that enable dose escalation while sparing adjacent normal tissue.
Fri Jun 26, 2020 03:00
By integrating data of the PLCO cancer screening trial, SCORE-risk charts and radiotherapy excess ratios, we were able to create risk charts estimating radiotherapy-induced lung cancer and cardiovascular mortality in female breast cancer patients. These risk models might be useful to individualize radiotherapy and optimize lung cancer and cardiovascular prevention and screening.
Fri Jun 26, 2020 03:00
Radiation therapy remains an essential component of cancer therapy for millions of patients annually in the United States and globally. Radiation therapy involves the focal deposition of ionizing radiation (IR) to the tumor and surrounding at-risk tissue compartments such as regional lymph nodes. The most common treatment approaches include external beam radiation therapy (EBRT) using high-energy photons, electrons, or protons, as well as brachytherapy and radionuclide therapy. Significant technical...
Fri Jun 26, 2020 03:00
Alongside radical prostatectomy, radiation therapy is an effective treatment modality for prostate cancer patients irrespective of risk group. Nevertheless, a considerable number of these patients are faced with isolated local failure of prostate cancer after radiation therapy with curative intent. Up to 10% of patients with a low-risk, 10-20% with an intermediate-risk and up to 30-37% with high-risk tumors will suffer local recurrence during follow-up [1–4]. Thus, the possibility of an effective...
Thu Jun 25, 2020 03:00
Since its first definition in 1995[1] by Hellman and Weichselbaum, the oligometastatic state has been focus of increasing attention from the oncologic community. The debate regarding the role of metastases directed therapy (MDT) in the oligometastatic setting is characterized by promising results from both large retrospective analysis[2–5] and some prospective trials[6–10], including recent published long-term results from Palma et al[11].
Thu Jun 25, 2020 03:00
CT-guided treatment delivery can improve target localization in mediastinal lymphoma patients treated with “butterfly” intensity-modulated radiotherapy and deep-inspiration breath hold. Although daily CT imaging adds additional radiation exposure, its use may be justified given the greater normal tissue sparing enabled by PTV margin reduction.
Thu Jun 25, 2020 03:00
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Neelima Panth, Justin M. Barnes, Matthew C. Simpson, Eric Adjei Boakye, Rosh K.V. Sethi, Mark A. Varvares, Nosayaba Osazuwa-Peters
Thu Jun 25, 2020 16:45
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Paola Bertuccio, Gianfranco Alicandro, Matteo Malvezzi, Greta Carioli, Paolo Boffetta, Fabio Levi, Carlo La Vecchia, Eva Negri
Thu Jun 25, 2020 16:45
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): D. Lokanatha, Syed Adil Hassan, Linu Abraham Jacob, M.C. Suresh Babu, K.N. Lokesh, A.H. Rudresha, L.K. Rajeev, Smitha Saldanha, Antony G.F. Thottian
Thu Jun 25, 2020 16:45
Abstract Purpose For step-and-shoot robotic stereotactic radiosurgery (SRS) the dose delivered over time, called local tumor-dose-rate (TDR), may strongly vary during treatment of multiple lesions. The authors sought to evaluate technical parameters influencing TDR and correlate TDR to clinical outcome. Material and methods A total of 23 patients with...
Thu Jun 25, 2020 03:00
Abstract Purpose Cancer stem cells (CSCs) are held accountable for the progress of head and neck squamous cell carcinoma (HNSCC). In the presented study, the authors evaluated the prognostic value of CSC markers in two particular HNSCC cohorts. Methods This two cohort study consisted of 85 patients with advanced stage HNSCC, treated with primary radio(chemo)therapy...
Thu Jun 25, 2020 03:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου